Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMichael SladeBarnes-Jewish HospitalFKFrank KuhrMenarini Group (Italy)PTPaola TononiCastellini (Italy)

Discussion

Loading...

Member takes

Implication

Prospective cohort reveals circulating multiple myeloma cells serve as a prognostic marker in CAR T cell therapies, suggesting their utility in monitoring treatment response.

Key Points

  • To assess the kinetics of circulating multiple myeloma cells and their prognostic value in patients undergoing CAR T cell therapy.
  • Prospective cohort study of patients treated with anti-BCMA CAR T cell therapy.
  • Samples collected at multiple time points for CMMC analysis via next-generation sequencing and other methodologies.
  • CMMCs were defined using specific cellular markers and assessed alongside bone marrow biopsies.
  • A substantial overall response rate of 97% was observed at day 100 post-therapy.
  • CMMCs presence declines rapidly post-infusion, showing decreased levels over time.
  • Next-generation sequencing captured most cytogenetic changes, identifying clinically actionable alterations in 75% of tested patients.

Cite This Study

Slade et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d16fhttps://doi.org/10.1182/blood-2025-5851
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant2025
  2. 2B cell kinetics on next generation sequencing after CAR T-cell therapy in multiple myeloma2025 · 1 citations
  3. 3Abstract 3619: Post CAR-T lymphocytosis as a surrogate of BCMA CAR-T expansion, response, and prognosis in multiple myeloma2024
  4. 4P46 | CIRCULATING PLASMA CELLS AS A DYNAMIC BIOMARKER IN MULTIPLE MYELOMA PATIENTS RECEIVING CAR-T AND BISPECIFIC ANTIBODY THERAPY2026
  5. 5BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025